Galmed Pharmaceuticals Ltd.

Nasdaq:GLMD

Pharmaceutical Preparations·RAMAT GAN, L3

Summary Financials

Revenue

$2.0M

+87.8% YoY

FY 2020

Adj. EBITDA

-$10.7M

-524.0% margin

FY 2020

Net Income

-$17.9M

-876.6% margin

FY 2024

EPS (Diluted)

$127.80

FY 2024

Stock Price

$0.63

-3.2%

2026-03-13

52W Range

$0.50 – $3.50

P/E Ratio

0.0x

Market Cap

$1.0M

Cash

$2.9M

FY 2024

Total Debt

$796,000

FY 2017

Net Cash

$2.1M

FY 2017

Enterprise Value

-$1.0M

Debt / EBITDA

0.2x

FY 2020

EV / EBITDA

0.1x

Employees

—

Revenue

$2.0M

+87.8% YoY

FY 2020

Adj. EBITDA

-$10.7M

-524.0% margin

FY 2020

Net Income

-$17.9M

-876.6% margin

FY 2024

EPS (Diluted)

$127.80

FY 2024

Stock Price

$0.63

-3.2%

2026-03-13

52W Range

$0.50 – $3.50

P/E Ratio

0.0x

Market Cap

$1.0M

Cash

$2.9M

FY 2024

Total Debt

$796,000

FY 2017

Net Cash

$2.1M

FY 2017

Enterprise Value

-$1.0M

Debt / EBITDA

0.2x

FY 2020

EV / EBITDA

0.1x

Employees

—